These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15989862)

  • 1. [Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy].
    Mahiques Santos L; Martínez Menchón T; Sánchez Carazo JL; Fortea Baixauli JM
    Med Clin (Barc); 2005 Jun; 125(4):159. PubMed ID: 15989862
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
    Newland MR; Weinstein A; Kerdel F
    Int J Dermatol; 2002 Jul; 41(7):449-52. PubMed ID: 12121565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of severe refractory psoriasis with infliximab].
    Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Oliver Martínez V; Soriano Navarro CJ; Fortea Baixauli JM
    Med Clin (Barc); 2004 Nov; 123(17):657-8. PubMed ID: 15563800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of severe psoriasis to infliximab.
    Mang R; Stege H; Ruzicka T; Krutmann J
    Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
    [No Abstract]   [Full Text] [Related]  

  • 6. [Our experience with infliximab in reclacitrant cases of psoriasis].
    Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis?
    Ingram JR; Anstey AV; Piguet V
    Br J Dermatol; 2012 Oct; 167(4):949-51. PubMed ID: 22486276
    [No Abstract]   [Full Text] [Related]  

  • 8. A review of the treatment of psoriasis with infliximab.
    Vamvouris T; Hadi S
    Rev Recent Clin Trials; 2006 Sep; 1(3):201-5. PubMed ID: 18473973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
    Thielen AM; Barde C; Saurat JH
    Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
    [No Abstract]   [Full Text] [Related]  

  • 10. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
    van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
    Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
    [No Abstract]   [Full Text] [Related]  

  • 12. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with infliximab biosimilar in psoriasis.
    Ricceri F; Pescitelli L; Lazzeri L; Prignano F
    Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab for the treatment of severe pustular psoriasis.
    Elewski BE
    J Am Acad Dermatol; 2002 Nov; 47(5):796-7. PubMed ID: 12399781
    [No Abstract]   [Full Text] [Related]  

  • 15. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
    Yip L; Harrison S; Foley P
    Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab for psoriasis.
    Gottlieb AB
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.